S&P 500   4,580.26 (+0.63%)
DOW   35,678.11 (+0.53%)
QQQ   381.79 (+0.47%)
AAPL   150.80 (+1.31%)
MSFT   321.82 (-0.42%)
FB   310.14 (-0.67%)
GOOGL   2,924.52 (+0.01%)
TSLA   1,069.99 (+3.10%)
AMZN   3,390.75 (-0.05%)
NVDA   246.95 (+1.00%)
BABA   167.67 (-0.92%)
NIO   39.80 (+1.25%)
CGC   12.85 (+0.55%)
GE   103.42 (-0.41%)
AMD   121.30 (-0.80%)
MU   69.46 (+1.79%)
T   25.43 (+1.48%)
F   17.28 (+11.41%)
ACB   6.91 (+1.02%)
DIS   169.70 (+0.09%)
PFE   43.46 (+1.14%)
BA   205.50 (-0.54%)
AMC   35.25 (+1.41%)
S&P 500   4,580.26 (+0.63%)
DOW   35,678.11 (+0.53%)
QQQ   381.79 (+0.47%)
AAPL   150.80 (+1.31%)
MSFT   321.82 (-0.42%)
FB   310.14 (-0.67%)
GOOGL   2,924.52 (+0.01%)
TSLA   1,069.99 (+3.10%)
AMZN   3,390.75 (-0.05%)
NVDA   246.95 (+1.00%)
BABA   167.67 (-0.92%)
NIO   39.80 (+1.25%)
CGC   12.85 (+0.55%)
GE   103.42 (-0.41%)
AMD   121.30 (-0.80%)
MU   69.46 (+1.79%)
T   25.43 (+1.48%)
F   17.28 (+11.41%)
ACB   6.91 (+1.02%)
DIS   169.70 (+0.09%)
PFE   43.46 (+1.14%)
BA   205.50 (-0.54%)
AMC   35.25 (+1.41%)
S&P 500   4,580.26 (+0.63%)
DOW   35,678.11 (+0.53%)
QQQ   381.79 (+0.47%)
AAPL   150.80 (+1.31%)
MSFT   321.82 (-0.42%)
FB   310.14 (-0.67%)
GOOGL   2,924.52 (+0.01%)
TSLA   1,069.99 (+3.10%)
AMZN   3,390.75 (-0.05%)
NVDA   246.95 (+1.00%)
BABA   167.67 (-0.92%)
NIO   39.80 (+1.25%)
CGC   12.85 (+0.55%)
GE   103.42 (-0.41%)
AMD   121.30 (-0.80%)
MU   69.46 (+1.79%)
T   25.43 (+1.48%)
F   17.28 (+11.41%)
ACB   6.91 (+1.02%)
DIS   169.70 (+0.09%)
PFE   43.46 (+1.14%)
BA   205.50 (-0.54%)
AMC   35.25 (+1.41%)
S&P 500   4,580.26 (+0.63%)
DOW   35,678.11 (+0.53%)
QQQ   381.79 (+0.47%)
AAPL   150.80 (+1.31%)
MSFT   321.82 (-0.42%)
FB   310.14 (-0.67%)
GOOGL   2,924.52 (+0.01%)
TSLA   1,069.99 (+3.10%)
AMZN   3,390.75 (-0.05%)
NVDA   246.95 (+1.00%)
BABA   167.67 (-0.92%)
NIO   39.80 (+1.25%)
CGC   12.85 (+0.55%)
GE   103.42 (-0.41%)
AMD   121.30 (-0.80%)
MU   69.46 (+1.79%)
T   25.43 (+1.48%)
F   17.28 (+11.41%)
ACB   6.91 (+1.02%)
DIS   169.70 (+0.09%)
PFE   43.46 (+1.14%)
BA   205.50 (-0.54%)
AMC   35.25 (+1.41%)
NASDAQ:MOLN

Molecular Partners Stock Forecast, Price & News

$19.07
-0.08 (-0.42 %)
(As of 10/27/2021 12:00 AM ET)
Add
Compare
Today's Range
$19.03
$19.10
50-Day Range
$18.52
$21.00
52-Week Range
$18.00
$21.33
Volume
1,964 shs
Average Volume
45,720 shs
Market Capitalization
$615.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive MOLN News and Ratings via Email

Sign-up to receive the latest news and ratings for Molecular Partners and its competitors with MarketBeat's FREE daily newsletter.


About Molecular Partners

Molecular Partners AG operates as a clinical-stage biopharmaceutical company. It is developing Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of wet age-related macular degeneration, as well as for diabetic macular edema; and MP0250 that binds and inhibit vascular endothelial growth factor and hepatocyte growth factor pathways, which restores clinical sensitivity to various standard-of-care therapies in multiple myeloma. The company is also developing MP0274 that is in Phase I clinical trials for HER2-positive solid tumors; MP0310, which is in Phase I clinical trials for immuno-oncology; MPO317, a tumor-localized immune agonist that activates immune cells in the tumor; and Peptide-MHC, a tumor-localized immune-cell agonist to attack tumors. It has strategic partnerships with Allergan, Inc. and Amgen SA; and collaboration with AGC Biologics to develop anti-COVID-19 DARPin program. Molecular Partners AG was founded in 2004 and is headquartered in Schlieren, Switzerland.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MOLN
Employees
152
Year Founded
N/A

Sales & Book Value

Annual Sales
$9.97 million

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$615.62 million
Next Earnings Date
N/A
Fiscal Year End
December 31
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.81 out of 5 stars

Medical Sector

793rd out of 1,372 stocks

Biological Products, Except Diagnostic Industry

120th out of 197 stocks

Analyst Opinion: 3.4Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Molecular Partners (NASDAQ:MOLN) Frequently Asked Questions

Is Molecular Partners a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Molecular Partners in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Molecular Partners stock.
View analyst ratings for Molecular Partners
or view top-rated stocks.

What stocks does MarketBeat like better than Molecular Partners?

Wall Street analysts have given Molecular Partners a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Molecular Partners wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Molecular Partners?

Molecular Partners saw a decline in short interest in the month of October. As of October 15th, there was short interest totaling 8,800 shares, a decline of 59.4% from the September 30th total of 21,700 shares. Based on an average trading volume of 20,600 shares, the days-to-cover ratio is currently 0.4 days.
View Molecular Partners' Short Interest
.

What price target have analysts set for MOLN?

5 brokerages have issued 12 month price objectives for Molecular Partners' stock. Their forecasts range from $19.52 to $35.00. On average, they anticipate Molecular Partners' share price to reach $26.51 in the next twelve months. This suggests a possible upside of 39.0% from the stock's current price.
View analysts' price targets for Molecular Partners
or view top-rated stocks among Wall Street analysts.

Who are Molecular Partners' key executives?

Molecular Partners' management team includes the following people:
  • Dr. Patrick Amstutz, Co-Founder, CEO, Member of Management Board & Director (Age 46, Pay $716.43k)
  • Dr. Michael Tobias Stumpp Ph.D., Co-Founder, COO & Member of Management Board (Age 49)
  • Mr. Andreas Emmenegger E.M.B.A., CFO & Member of Management Board (Age 55)
  • Dr. Nicolas Leupin M.B.A., Ph.D., M.D., MBA, Chief Medical Officer & Member of Management Board (Age 48)
  • Mr. Daniel Steiner Ph.D., Sr. VP of Research
  • Dr. Hans Kaspar Binz Ph.D., VP of Technology
  • Mr. Seth D. Lewis, Sr. VP of Investor Relations, Communications & Strategy
  • Mr. Julien Gander L.L.M., Gen. Counsel, VP of Legal & Sec. of the Board
  • Mr. Thomas Schwerzmann, VP of HR
  • Dr. Pamela A. Trail, Strategic Consultant (Age 65)

When did Molecular Partners IPO?

(MOLN) raised $81 million in an IPO on Wednesday, June 16th 2021. The company issued 3,000,000 shares at $27.14 per share. J.P. Morgan, SVB Leerink, Cowen and RBC Capital Markets acted as the underwriters for the IPO and Kempen & Co. was co-manager.

What is Molecular Partners' stock symbol?

Molecular Partners trades on the NASDAQ under the ticker symbol "MOLN."

When does Molecular Partners' lock-up period expire?

Molecular Partners' lock-up period expires on Monday, December 13th. Molecular Partners had issued 3,000,000 shares in its initial public offering on June 16th. The total size of the offering was $63,750,000 based on an initial share price of $21.25. After the end of Molecular Partners' lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

How do I buy shares of Molecular Partners?

Shares of MOLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Molecular Partners' stock price today?

One share of MOLN stock can currently be purchased for approximately $19.07.

How much money does Molecular Partners make?

Molecular Partners has a market capitalization of $615.62 million and generates $9.97 million in revenue each year.

How many employees does Molecular Partners have?

Molecular Partners employs 152 workers across the globe.

What is Molecular Partners' official website?

The official website for Molecular Partners is www.molecularpartners.com.

How can I contact Molecular Partners?

The company can be reached via phone at 41-44-755-7700.


This page was last updated on 10/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.